Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Jun 17, 2021
Posted in: News, Investor updates

Home » Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Jun 17, 2021
Posted in: News, Investor updates

The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 17 June, 2021.

Please click to review the full announcement at ASX.

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

September 4, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent

January 31, 2026

Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Related Articles

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list